Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

12.08 -2.42

Resumen

Variación precio

24h

Actual

Mínimo

11.64

Máximo

12.54

Métricas clave

By Trading Economics

Ingresos

7M

8M

Ventas

3.7M

139M

P/B

Media del Sector

115.5

68.51

Margen de beneficios

5.724

Empleados

1,790

EBITDA

18M

4M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+16.15% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

95M

2B

Apertura anterior

14.5

Cierre anterior

12.08

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 ago 2026, 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

10 ago 2026, 23:52 UTC

Event
News
Social Media

Plug Power shares are higher in after-market trading following strong second-quarter results that exceeded analyst expectations and an improved revenue growth outlook.

10 ago 2026, 23:51 UTC

News

First Horizon Corp shares rise in after-market hours following James Petrillo's appointment as Vice President, De Novo New Build Leader to enhance banking centers.

10 ago 2026, 23:51 UTC

News
Social Media

Riot Platforms reported Q2 revenue of $174.2 million, exceeding expectations. Shares rose sharply in after-hours trading following a major data center lease announcement.

10 ago 2026, 23:51 UTC

News
Social Media

FutureFuel Corp reported second-quarter revenues of $78.7 million, a 120.6% increase year-over-year. Shares are trading higher in after-market hours following the results.

10 ago 2026, 23:51 UTC

Event
News
Social Media

Upwork Inc. shares fell sharply in after-market hours following disappointing second-quarter results and lowered full-year revenue guidance of $730 million to $750 million.

10 ago 2026, 23:46 UTC

News

Fortuna Silver Mines acquires the Bambadji Project for $200 million, boosting growth potential in West Africa. Shares are higher in after-market trading.

10 ago 2026, 23:42 UTC

News

AT&T Inc. filed a $1.1 billion term sheet for floating rate notes due in 2028, contributing to lower shares in after-market trading.

10 ago 2026, 23:41 UTC

News

Kyndryl Holdings plans to acquire Healthcare IT Leaders to enhance its healthcare capabilities. Shares are trading higher in after-market hours following the announcement.

10 ago 2026, 23:41 UTC

News

Analysts adjusted price targets for Insmed Inc. after recent evaluations. Shares are higher in after-market trading, reflecting positive sentiment amid these actions.

10 ago 2026, 23:41 UTC

News

Enphase Energy shares are lower in after-market trading following governance enhancements announced by the board after its 2026 Annual Meeting vote.

10 ago 2026, 23:41 UTC

News

Toast Inc. shares are trading lower in after-market hours following Elena Gomez's sale of 17,076 shares, reducing her ownership by 9%.

10 ago 2026, 23:41 UTC

News

Harrow Inc shares declined in after-market hours following a second-quarter EPS miss of -$0.46, despite revenue of $70.66 million exceeding expectations.

10 ago 2026, 23:41 UTC

News

Hf Foods Group Inc reported strong Q2 results, with revenue of $323.8 million and GAAP net income of $2.6 million, driving shares higher in after-market hours.

10 ago 2026, 23:41 UTC

News

Curtiss-Wright Corp raised its share repurchase program to $160 million, boosting investor sentiment as shares gained during after-market hours.

10 ago 2026, 23:41 UTC

News
Social Media

Hims & Hers Health reported a net loss of $86.3 million in Q2, contributing to a decline in share price during after-market trading.

10 ago 2026, 23:41 UTC

News

Rapid7 shares rise in after-hours trading following second-quarter results that exceeded expectations and positive third-quarter guidance.

10 ago 2026, 23:41 UTC

Event
News

Alcon AG reported second-quarter adjusted EPS of $0.84, surpassing estimates. The company raised its fiscal 2026 EPS guidance, boosting shares in after-market hours.

10 ago 2026, 23:41 UTC

News
Social Media

Entravision Communications shares fell sharply after reporting mixed Q2 results, with earnings of $0.19 and revenues of $227.9 million amid declining broadcast advertising revenue.

10 ago 2026, 23:41 UTC

News

Celsius Holdings Inc. shares are lower in after-market trading following significant leadership changes, including the departure of President Eric Hanson.

10 ago 2026, 23:36 UTC

News

Purple Innovation shares fell after the company reported Q2 2026 earnings of -$0.74, missing estimates, and reduced full-year revenue guidance to $420 million to $440 million.

10 ago 2026, 23:36 UTC

Correlated Moves
News

Pomerantz LLP has filed a class action lawsuit against Zillow Group Inc, contributing to a decline in shares during after-market trading.

10 ago 2026, 23:36 UTC

News

Valero Energy shares are higher in after-market trading, reflecting a five-year average annual return of 36.59%, turning a $100 investment into $468.33.

10 ago 2026, 23:36 UTC

News

Phillips Edison & Co Inc shares are lower in after-market hours following a $400 million stock sale announcement, raising concerns over potential dilution.

10 ago 2026, 23:31 UTC

News

Tactile Systems Technology shares fell in after-market hours following a revenue guidance cut, despite a rise in net income and adjusted EBITDA surpassing expectations.

10 ago 2026, 23:31 UTC

News

L3Harris Technologies completed a successful hot-fire test for the Next Generation Interceptor program, boosting shares in after-market trading.

10 ago 2026, 23:31 UTC

News

Definitive Healthcare reported Q2 adjusted EPS of $0.05, exceeding estimates. The stock rose sharply during after-market hours amid positive guidance and CEO comments.

10 ago 2026, 23:26 UTC

News

Rocket Pharmaceuticals reported Q2 net income of $123.2 million, with EPS of $1.08, significantly exceeding estimates. Shares traded higher in after-market hours.

10 ago 2026, 23:26 UTC

News

RadNet Inc reported record Q2 revenue and adjusted EBITDA. Shares are trading higher in after-market hours, reflecting positive investor sentiment following the earnings report.

10 ago 2026, 23:21 UTC

News
Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

16.15% repunte

Estimación a 12 Meses

Media 14.53 USD  16.15%

Máximo 16 USD

Mínimo 13.6 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

1

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat